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Abstract
Background: Advancing knowledge in molecular pathogenesis of hepatocellular carcinoma (HCC) opens up new
horizons in the diagnostic, prognostic and therapeutic perspectives. Assessing the expression of molecular targets
prior to definitive treatment is gaining importance in clinical practice. In this study, we investigated the variation in
expression pattern of stemness markers in synchronous multi-focal HCC.
Methods: In the first cohort, 21 liver explants with multi-focal HCC were examined for expression of stemness
markers EpCAM, Sox9 and CK19 by immunohistochemistry (IHC). Expression data of 50 tumor nodules were
analyzed to determine the concordance of expression among nodules in the same livers. In the second cohort, 14
tumor nodules from 6 multi-focal HCC cases proven as intra-hepatic metastasis were examined for Soc9
immunoexpression.
Results: In the first cohort, thirty nodules from 16 cases expressed one or more markers, with Sox9 being most
frequently expressed. Complete concordance of expression pattern for all 3 markers was observed in 6 cases.
Discrepancy of staining degree was noted in 4 cases for EpCAM, 14 cases for Sox9, and 6 cases for CK19. A two-tier
or three-tier difference in staining scores was noted in 5 cases for Sox9 and one case for CK19. With Sox9, identical
tumor morphology in terms of Edmondson grading and growth pattern did not infer the same degree of
immunoexpression; and the largest tumor nodule was not representative of highest IHC score. In the second
cohort of intra-hepatic metastasis, complete concordance of Sox9 expression level was observed in 5 out of 6 cases;
while the remaining case showed a 1-tier difference of positive staining.
Conclusions: Our findings suggested that clonality of tumor nodules is apparently an important factor to infer
immunoexpression pattern. When there is limited information to discern multiple primaries versus intra-hepatic
metastasis in multi-focal HCC, discordant degree of stemness markers expression among tumor nodules was
commonly observed especially for markers with higher frequency of expression. Pathological features alone do not
necessarily indicate the expression pattern of the synchronous nodule and in this scenario examination of each
tumor nodule is justified.
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Background
Cancer stemness has been one of the research spotlights
in recent years. The relevance of stemness properties to
tumor initiation, recurrence, metastasis and chemoresis-
tance endows their significant clinical implications in he-
patocellular carcinoma (HCC) [1–4]. Therefore, molecular
markers conferring stemness phenotypes are appealing
candidates for interrogation of the biology of HCC. A
number of functional stemness markers in HCC have
been identified and characterized such as CK19 [5], CD24
[6], CD133 [7], Sox9 [8] and EpCAM [9]. Translating
these findings to clinical practice, assessing the expression
of stemness markers in HCC samples is a potential means
to define the prognosis of HCC patients and to devise reg-
imens with targeted therapy. Expression of stemness
markers in HCC was found to be associated with more ag-
gressive biological behavior [10–13]. The stemness elem-
ent in HCC has also brought about evolution of
classification and nomenclature of primary liver cancer
[14]. For instance, expression of CK19 in an HCC by
morphology was regarded by some as “HCC with stem/
progenitor cell immunophenotype” [15].
Immunohistochemical (IHC) expression of markers in
tumor tissues can be heterogeneous. This also applies to
cases presented with synchronous tumor nodules. HCC
frequently occurs as multiple tumor nodules which may
represent multi-centric tumors or intra-hepatic metasta-
sis. In daily pathology practice, distinction between the
two may not be feasible in every single case. However, in
view of the foreseeable gaining popularity of liver tumor bi-
opsy prior to treatment for delineation of gene expression
profile, the potential variation of expression patterns among
synchronous tumor nodules warrant further attention and
clarification. In this study, we asked to what extent the ex-
pression of well-characterized stemness markers might vary
among different tumor nodules in the same liver speci-
mens. To answer this question, we made use of the liver ex-
plant model to assess the IHC expression of stemness
markers EpCAM, CK19 and Sox9 in synchronous HCC
tumor nodules. In order to gain further insights how
clonality of the tumor nodules might affect the immunoex-
pression, we also included a second cohort of multi-focal
HCC cases with proven evidence of intra-hepatic metastasis
for comparison.
Methods
Clinical samples
Human tissues from the HCC cohort were obtained
from patients undergoing liver transplantation at Queen
Mary Hospital, Hong Kong from 2009 to 2016. All spec-
imens collected fixed in 10% formalin for paraffin em-
bedding. Representative tissue block(s) were taken from
each tumor nodule identified on gross examination.
Liver specimens with 2 to 4 tumor nodules were
included in this study. Cases with tumor nodules show-
ing extensive necrosis were excluded. Dominant nodule
was defined as the tumor nodule with the greatest
dimension. The second HCC cohort of intra-hepatic me-
tastasis comprised 6 cases resected from Queen Mary
Hospital, Hong Kong from 1993 to 1999. Use of clinical
samples was approved by the Institutional Review Board
of the University of Hong Kong/Hospital Authority
Hong Kong West Cluster (Ref. UW11–424). Clinical in-
formation was retrieved from patients’ records.
Immunohistochemistry
IHC staining for EpCAM, CK19 and Sox9 were per-
formed on formalin-fixed, paraffin-embedded sections
using labeled horseradish peroxidase (HRP) method.
After heat antigen retrieval with Tris- EDTA buffer
(Sox9, CK19) or Protease K enzyme antigen retrieval
(EpCAM), endogenous peroxidase activities were
quenched by 3% H2O2. The sections were immersed in
serum free-protein block solution (Dako) and incubated
with anti-Sox9 (Millipore AB5535, MA at dilution
1:1000), anti-CK19 (ab52625, Abcam) at dilution
1:1000), and anti-EpCAM (M0804, Dako at dilution
1:100) at 4°C overnight. The sections were thoroughly
washed and incubated with EnvisionTM HRP-
conjugated secondary antibody (Dako). Positive signals
were visualized using 3,3′-diaminobenzidine (Dako). Nu-
clei were counterstained with hematoxylin.
Histological assessment
The histological sections were reviewed by a liver path-
ologist (RCL) to confirm the diagnosis of HCC and to
ascertain the viability of tumor cells. Tumor cell grading
by the Edmondson grading system [16] and growth pat-
tern of tumor cells were assessed. IHC expression results
were examined with reference to a semi-quantitative
method defined by the percentage of positive-staining
tumor cells in the sections, with score 0 (negative): no
staining; score 1: 1–33%; score 2: 34–66%; score 3: 67%
or more.
Results
Clinicopathological parameters of the study cohort
The 21 liver explants came from 19 male patients and 2
female patients ranging from 49 to 66 years of age. All
explant livers were cirrhotic, of which the etiology is in
majority chronic hepatitis B virus infection (n = 16),
followed by chronic hepatitis C virus infection (n = 3),
alcoholic liver disease (n = 1) and cryptogenic (n = 1).
Altogether 50 HCC nodules were assessed in the 21
cases. Two tumor nodules were present in 14 cases,
three tumor nodules in 6, and 4 nodules in one case.
The size of the tumor nodules ranged from 1 to 6.3 cm.
The dimension of the dominant nodules ranged from 2
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Table 1 Clinicopathological features of the first cohort
Case no. Gender/Age Etiology Nodule designation Size of tumor nodule (mm) Gradinga Growth pattern#
1 M/60 HBV i
ii
25
15
2
2
T
T
2 M/56 HBV i
ii
35
30
2
2
T
T + A
3 M/58 HBV i
ii
iii
iv
50
30
20
10
2
2
2
3
T + A
A + T
T
T
4 M/59 HBV i
ii
22
18
3
2
T
A + T
5 M/57 HCV i
ii
40
30
2
2
T
T
6 M/51 HBV i
ii
22
10
2
2
T
T
7 M/66 HBV i
ii
63
14
2
3
T
T
8 M/49 HBV i
ii
iii
25
20
12
2
2
3
T
T
T
9 M/50 HCV i
ii
40
20
2
2
T
A + T
10 M/65 HBV i
ii
iii
45
20
15
2
2
3
A + T
T
T
11 M/60 HBV i
ii
50
25
3
2
T
T
12 M/55 HBV i
ii
20
10
3
2
T
T
13 M/58 HBV i
ii
iii
35
25
20
2
2
2
T
T
T
14 M/46 HBV i
ii
20
15
2
2
T
T
15 M/63 ALD i
ii
iii
30
25
25
3
2
3
T
T
T
16 M/65 HCV i
ii
45
18
3
3
T
T
17 M/53 HBV i
ii
iii
20
13
13
2
3
2
T + A
T
T
18 M/53 HBV i
ii
34
10
2
3
T + A
T
19 F/60 HBV i
ii
iii
40
20
10
2
2
2
T + A
T
T
20 M/63 HBV i
ii
45
40
2
2
T
T
21 F/60 cryptogenic i
ii
50
30
2
2
T
T
agrading by Edmondson system
#T: trabecular; A: pseudoacinar; denoted as “predominant pattern + minor pattern” in cases with mixed pattern
HBV: hepatitis B virus
HCV: hepatitis C virus
ALD: alcoholic liver disease
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to 6.3 cm. For the Edmondson grading on tumor cell
differentiation, 37 (of 50) nodules belonged to grade II
and 13 belonged to grade III. Ten of the 21 cases com-
prised a mixed composition of grades II and III tumor
nodules. Majority of tumor nodules (41 of 50) showed a
trabecular growth pattern while the remaining showed a
mixed trabecular and pseudoacinar pattern. The clinico-
pathological parameters of the 21 cases were summa-
rized in Table 1.
Immunohistochemical expression of the stemness markers
The immunohistochemical expression results were pre-
sented in Table 2. EpCAM was expressed in 1 tumor
nodule each from 4 cases. Sox9 was expressed in 30
nodules from 16 cases; CK19 was expressed in 6 nodules
from 6 cases (Fig. 1). On the staining scores, all positive
staining for EpCAM and all except one positive staining
for CK19 belonged to score 1. Sox9 staining consisted of
a spectrum of scores 1 to 3. Thirty nodules expressed
one or more markers; 5 cases did not express any of the
3 markers in all tumor nodules.
Concordance of IHC expression in multi-focal HCC
Complete concordance of expression pattern for all 3
markers was observed in 6 cases including the 5 cases
showing no expression of any markers in all tumor nod-
ules. Discrepancy of staining score was noted in 4 cases
for EpCAM, 14 cases for Sox9, and 6 cases for CK19.
“One-tier” discrepancy (difference by 1 grading score)
was common for all 3 stains, and including all 4 cases
for EpCAM and 5 cases for CK19. A two-tier or three-
tier difference was noted in 5 cases for Sox9 and one
case for CK19. A “positive-negative discrepancy” (i.e. 0
versus 1 or 2 or 3) for anyone stain was identified in 11
cases, with vast majority involving a “0” versus “1”
difference.
Seven cases in our cohort consisted of 3 or more
tumor nodules. Concordant staining score was observed
in 2 cases for EpCAM, 6 for Sox9 and 6 for CK19. In 4
cases (case#3, #10, #17, #19), the scoring pattern for
each of the tumor nodules was different from one an-
other. In 2 cases (case #8, #15), two of the three tumor
nodules demonstrated identical scores and in the
remaining case (case#13), there was no expression for all
three markers in all tumor nodules.
Correlation of expression pattern and pathological
parameters
Eleven cases showed identical tumor morphology in
terms of tumor grading and growth pattern in 2 or more
tumor nodules. Among the 11 cases, concordant stain-
ing score was noted in 11, 3 and 10 cases for EpCAM,
Sox9 and CK19 respectively. Identical staining pattern
for all 3 markers was noted in 2 cases. Lastly, we
attempted to look into the potential significance of the
dominant nodule, the tumor nodule of greatest dimen-
sion of each liver explant specimen. The dominant
Table 2 Immunohistochemical expression results of the tumor
nodules in the first cohort
Case no. Nodule designation EpCAM% Sox9% CK19%
1 i
ii
0
0
1
0
0
0
2 i
ii
0
0
0
0
0
0
3 i
ii
iii
iv
1
0
0
0
1
1
1
0
0
0
1
0
4 i
ii
0
0
1
1
0
0
5 i
ii
0
0
3
1
0
0
6 i
ii
0
0
3
1
0
0
7 i
ii
0
0
0
3
0
0
8 i
ii
iii
0
0
0
1
1
2
0
0
0
9 i
ii
1
0
2
2
0
0
10 i
ii
iii
0
1
0
0
2
1
0
1
0
11 i
ii
0
0
0
0
0
0
12 i
ii
1
0
2
1
3
0
13 i
ii
iii
0
0
0
0
0
0
0
0
0
14 i
ii
0
0
0
1
0
1
15 i
ii
iii
0
0
0
2
1
1
0
0
0
16 i
ii
0
0
0
1
0
0
17 i
ii
iii
0
0
0
0
1
1
0
1
0
18 i
ii
0
0
0
0
0
0
19 i
ii
iii
0
0
0
2
0
1
1
0
0
20 i
ii
0
0
0
0
0
0
21 i
ii
0
0
0
1
0
0
%score 0: no staining; score 1: 1–33%; score 2: 34–66%; score 3: >66%
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nodule corresponded to the highest score in 20 cases for
EpCAM, 4 cases for Sox9 and 17 cases for CK19.
Sox9 expression in HCC cohort of intra-hepatic metastasis
Given that the tumor nodules from multi-focal HCC
could possibly represent multiple primaries or intra-
hepatic metastasis, we attempted to investigate how
clonality may affect the results. Since Sox9 is the most
frequently expressed stemness marker from our findings
above, we proceeded to examine the immunohistochem-
ical expression of Sox9 in a cohort of 6 multi-focal HCC
cases, which were proven to be intra-hepatic metastasis as
determined by DNA fingerprinting using loss of heterozy-
gosity (LOH) assay, comparative genomic hybridization
(CGH) [17]. Results of 14 nodules from 6 cases were
assessed and presented in Table 3. Complete concordance
in staining score was observed in 5 cases. In the remaining
one case, the two tumor nodules showed score 1 and
score 2 respectively.
Discussion
In this study, we assessed and compared the immunohis-
tochemical expression of stemness markers EpCAM,
Sox9 and CK19 in HCC tissues from a cohort of liver
explant cases consisting of multiple tumor nodules. Sox9
was most readily expressed in the tumor nodules the co-
hort, followed by CK19 and then EpCAM. The expres-
sion rates were more or less consistent with those stated
in previous reports [8, 10, 11]. Complete concordance of
expression pattern for all 3 markers was present in 6
cases. Of note, 5 cases showed no expression for all
three markers and the concordance could be partly at-
tributed to the low expression rates of some markers
such as EpCAM and CK19. Discrepancy in expression
scores was a common event, and a two-tier or three-tier
discrepancy was noted in 6 (about one-fourth) cases
mainly involving Sox9 staining. On the other hand, Sox9
expression in the intra-hepatic metastasis cohort re-
vealed a high degree of concordance.
The discrepancy in IHC score among the tumor nodules
within the same liver specimens could possibly be ex-
plained in part by intra-tumoral heterogeneity [18, 19].
Yet in routine pathology practice, in view of the concerns
for resources and cost-effectiveness, it is impractical to
perform the same IHC stain on multiple tissue blocks
from the same tumor nodule. As a matter of fact, core bi-
opsy is usually the type of specimen available for initial
pathological diagnosis.
In this study, we attempted to explore whether a mor-
phological concordance among tumor nodules could be
inferring an identical pattern of stemness marker immu-
noexpression. While it was apparently the case for
Fig. 1 Representative images of immunohistochemical staining in the HCC tumor tissue (case#12). (A) H&E, (B) EpCAM, (C) Sox9 and (D) CK19
(×200 magnification)
Table 3 Sox9 immunohistochemical expression results of the
tumor nodules in the intra-hepatic metastasis cohort
Case no./Sox9 expression nodule 1 nodule 2 nodule 3
22 2 2 2
23 1 1 1
24 3 3 n.a.
25 3 3 n.a.
26 2 1 n.a.
27 1 1 n.a.
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EpCAM and CK19, the results were possibly due to the
relative low frequency of expression with these two
markers. For Sox9 staining, an identical morphology cor-
responded to the same staining score in only minority of
cases. Similarly, the expression of Sox9 in the dominant
nodule was representative of the highest degree among all
tumor nodules in the same liver specimen in only 14 of 22
cases. The above results suggested that pathological
parameters alone may not be dependable for estimating
the stemness markers expression of all tumor nodules in
the same liver especially for markers with higher fre-
quency of expression in HCC. Thus targeting the tumor
nodule of greatest dimension only at image-guided biopsy
may result in suboptimal characterization.
Liver transplantation is a best curative treatment
modality for HCC. In that availability of liver grafts is
always a concern and this leads to the introduction of
various bridging therapies such as high-intensity focused
ultrasound, trans-arterial chemoembolization and more
recently stereotactic body radiotherapy [20, 21] which
aim at tumor control while awaiting suitable grafts. With
accumulating knowledge in the molecular pathogenesis
of HCC, the spectrum of neoadjuvant therapy is antici-
pated to be expanding. Targeted therapy against func-
tional molecular markers conferring stemness properties
is a promising direction in this regard. In addition, re-
cent studies indicated a potential role of stemness
marker expression signature for prognostication and ex-
tension of inclusion criteria for HCC patients to be
treated by liver transplantation [22]. In view of this
evolving picture of clinical practice, our present study
serves as a pilot investigation on the variation of well-
characterized stemness markers expression in synchron-
ous multi-focal HCC.
Conclusion
Despite the fact that we do not have information for
all the cases to determine the clonality of the tumor
nodules at a molecular level such as by loss-of-
heterozygosity analysis of specific DNA microsatellite
loci or genomic studies [23], our study results provide
some insights from a practical point of view concern-
ing the heterogeneity of stemness markers expression
among synchronous tumor nodules in HCC. When
discerning between multiple primaries or intra-hepatic
metastasis is limited, expression of stemness markers
can be heterogeneous among tumor nodules and
evaluation of one nodule is unlikely to provide insight
on the expression pattern of other nodules. Our find-
ings suggested the significance of assessing expression
of all nodules at initial diagnosis. Moreover, validation
works in the future would be warranted to draw con-
clusions for individual markers.
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